Cite
HARVARD Citation
Kosiborod, M. et al. (2021). Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 9 (9), pp. 586-594. [Online].